Weill Cornell College — research payments reported

By program year

5 rows

Year	Kind	Amount	Payments
2025	Research	$202,325	9
2024	Research	$315,844	15
2023	Research	$96,823	9
2021	Research	$24,881	2
2020	Research	$119,385	6

Breakdown

Who paid Research payments · program years 2020–2025

Celgene Corporation $574,205 23 payments
GlaxoSmithKline, LLC. $100,940 17 payments
AstraZeneca Pharmaceuticals LP $84,114 1 payment

Studies the money was for Research payments · program years 2020–2025

A Phase 3, Multicenter, Randomized, Open-label Study to Compare the Efficacy and Safety of bb2121 Versus Standard Regimens in Subjects with Relapsed and Refractory Multiple Myeloma (RRMM) (KarMMa-3) $121,303 1 payment
A Randomized, Double-Blind, Phase 3 Comparison of Platinum-Based Thera $100,940 17 payments
Phase II Trial of Carboplatin, Etoposide, and Durvalumab with Sub-Ablative SBRT in Patients with Newly Diagnosed Stage IV Small Cell Lung Cancer $84,114 1 payment
PhIII RPC1063 Open Label Extension Moderate to Severe in UC (RPC01-3102) (BMS Study Number: IM047-P23) $68,903 1 payment
Phase 1 Escalation/Expansion in NHL (CC-97540-NHL-001) $48,871 1 payment
Phase I/IIA RRMM 1-3 prior lines alnuc+CELMoD - A Phase 1b/2a, Multicenter, Open-label Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Alnuctamab in Combination with Mezigdomide in Participants wit $48,125 1 payment
Expanded Access Protocol (EAP) for Patients Receiving Idecabtagene Vicleucel (ide-cel) that is Non-conforming for Commercial Release $38,500 2 payments
Expanded Access Protocol (EAP) For Subjects Receiving Lisocabtagene Maraleucel That Is Nonconforming For Commercial Release $35,971 1 payment
A Phase 3b, Open-label, Single-arm, Rollover Study to Evaluate Long-term Safety in Subjects Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials $30,591 1 payment
An Open-Label, Phase 1/2 Study of JCAR017 in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma $28,662 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.